Elizabeth Nauman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Elizabeth Nauman has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Lizheng Shi
Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University
6 shared publications - Alessandra Nina Bazzano
Department of Maternal and Child Health, University of North Carolina Chapel Hill School of Global Public Health, Chapel Hill, USA
5 shared publications - Eboni G. Price-Haywood
Center for Outcomes and Health Services Research, Ochsner Health, New Orleans, LA
3 shared publications - Elizabeth A. Shenkman
University of Florida College of Medicine, Gainesville, FL
3 shared publications - Alisha Monnette
Department of Health Policy and Management, Tulane University School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 1900, New Orleans, LA 70112, USA
2 shared publications - Charles Stoecker
Department of Health Policy and Management, Celia Scott Weatherhead School of Public Health and Tropical Medicine, Tulane University , New Orleans, Louisiana
2 shared publications
Latest Publications
- Open Access
- 8 January 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (3S) , S213-S218
Partnerships With Health Plans to Link Data From Electronic Health Records to Claims for Research Using PCORnet®
Health plans and public payers (ie, Medicare and Medicaid) maintain records of millions of transactions between patients and health care providers from claims submitted by hospitals, clinics, pharmacies, and other care settings. A major use of claims data in research is to supplement the information contained in patients’ medical records. PCORnet is a large, distributed “network of networks” funded by the Patient-Centered Outcomes Research Institute (PCORI) to improve the nation’s capacity to efficiently conduct definitive health research. Seventy-eight partner health systems nationwide map clinical data from their electronic health records to the PCORnet ® Common Data Model (CDM) so that the data may be efficiently used for research purposes. The ability to link data from electronic health records in the PCORnet infrastructure with complementary data from other sources, such as health insurance claims, further enhances the capacity for comparative clinical effectiveness research (CER). This commentary showcases the health plan partnerships of 3 PCORnet ® Clinical Research Networks (CRNs)—REACHnet, PaTH, and OneFlorida+—that enhance the capacity for CER involving linked clinical and claims data. We describe the transferable regulatory and technical infrastructures in place to efficiently link data for research purposes. To demonstrate these partnerships and data linkage in action, we also discuss research use cases pertaining to weight-related outcomes and diabetes that align with payers’ interests in chronic disease management.
- 8 January 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (3S) , S213-S218
Open AccessPartnerships With Health Plans to Link Data From Electronic Health Records to Claims for Research Using PCORnet®
Health plans and public payers (ie, Medicare and Medicaid) maintain records of millions of transactions between patients and health care providers from claims submitted by hospitals, clinics, pharmacies, and other care settings. A major use of claims data in research is to supplement the information contained in patients’ medical records. PCORnet is a large, distributed “network of networks” funded by the Patient-Centered Outcomes Research Institute (PCORI) to improve the nation’s capacity to efficiently conduct definitive health research. Seventy-eight partner health systems nationwide map clinical data from their electronic health records to the PCORnet ® Common Data Model (CDM) so that the data may be efficiently used for research purposes. The ability to link data from electronic health records in the PCORnet infrastructure with complementary data from other sources, such as health insurance claims, further enhances the capacity for comparative clinical effectiveness research (CER). This commentary showcases the health plan partnerships of 3 PCORnet ® Clinical Research Networks (CRNs)—REACHnet, PaTH, and OneFlorida+—that enhance the capacity for CER involving linked clinical and claims data. We describe the transferable regulatory and technical infrastructures in place to efficiently link data for research purposes. To demonstrate these partnerships and data linkage in action, we also discuss research use cases pertaining to weight-related outcomes and diabetes that align with payers’ interests in chronic disease management.
- Open Access
- 8 January 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (3S) , S251-S257
Characteristics of Pregnancy-related Health Events Across Care Settings Nationwide in PCORnet®
The maternal mortality rate in the United States is higher than peer countries throughout the world. There is a critical need to implement and evaluate the effectiveness of interventions to address factors that contribute to maternal mortality and morbidity (MMM). Legislation passed by the US Congress in 2019 reauthorized funding for the Patient-Centered Outcomes Research Institute (PCORI) and identified maternal morbidity and mortality as a research priority. PCORnet ® is a large, distributed “network of networks” funded by PCORI to improve the nation’s capacity to efficiently conduct definitive health research. PCORnet ® Network Partners convened a workgroup of experts in topics related to MMM—including patient stakeholders—and developed an exploratory query to identify and characterize the cohort of patients with pregnancy-related health events served by health systems participating in PCORnet. This article presents query results for 1.1 million pregnancies resulting in delivery or interruption that occurred between July 28, 2021, and July 28, 2023 among patients receiving care at 72 sites participating in PCORnet. Three percent of patients experienced severe maternal morbidity, and 357 cases of mortality were recorded. The results also include occurrence of mental and physical comorbidities in the prenatal, peripartum, and postpartum periods. These data are intended to support use of the PCORnet research infrastructure to produce evidence that matters to patients, caregivers, and the broader public health and health care communities. We also discuss ways to enhance the PCORnet infrastructure to accelerate maternal health research, including work that is currently underway to augment data pertinent to studying MMM.
- 8 January 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (3S) , S251-S257
Open AccessCharacteristics of Pregnancy-related Health Events Across Care Settings Nationwide in PCORnet®
The maternal mortality rate in the United States is higher than peer countries throughout the world. There is a critical need to implement and evaluate the effectiveness of interventions to address factors that contribute to maternal mortality and morbidity (MMM). Legislation passed by the US Congress in 2019 reauthorized funding for the Patient-Centered Outcomes Research Institute (PCORI) and identified maternal morbidity and mortality as a research priority. PCORnet ® is a large, distributed “network of networks” funded by PCORI to improve the nation’s capacity to efficiently conduct definitive health research. PCORnet ® Network Partners convened a workgroup of experts in topics related to MMM—including patient stakeholders—and developed an exploratory query to identify and characterize the cohort of patients with pregnancy-related health events served by health systems participating in PCORnet. This article presents query results for 1.1 million pregnancies resulting in delivery or interruption that occurred between July 28, 2021, and July 28, 2023 among patients receiving care at 72 sites participating in PCORnet. Three percent of patients experienced severe maternal morbidity, and 357 cases of mortality were recorded. The results also include occurrence of mental and physical comorbidities in the prenatal, peripartum, and postpartum periods. These data are intended to support use of the PCORnet research infrastructure to produce evidence that matters to patients, caregivers, and the broader public health and health care communities. We also discuss ways to enhance the PCORnet infrastructure to accelerate maternal health research, including work that is currently underway to augment data pertinent to studying MMM.
- Open Access
- 1 January 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e43583
Optimizing Telehealth for Diabetes Management in the Deep South of the United States: Qualitative Study of Barriers and Facilitators on the Patient and Clinician Journey
Background: The Deep South of the United States, and Louisiana in particular, bears a greater burden of obesity, diabetes, and heart disease compared with other regions in the United States. Throughout the COVID-19 pandemic, there has been a substantial increase in telehealth visits for diabetes management to protect the safety of patients. Although there have been significant advancements in telehealth and chronic disease management, little is known about patient and provider perspectives on the challenges and benefits of telehealth visits among people living with diabetes and providers who care for patients with diabetes in Louisiana. Objective: This study aimed to explore barriers, facilitators, challenges, and benefits to telehealth for patients with diabetes and health care providers as they transitioned from in-person to remote care during the early COVID-19 pandemic to understand potential optimization. Methods: A total of 24 semistructured qualitative interviews were conducted with 18 patients living with diabetes and 6 clinicians who served patients with diabetes to explore their experiences and perceptions of telehealth services for diabetes care. Approximately half of the participants identified as Black or African American, half as White, and 75% as female. Interviews were recorded, transcribed, and coded by experienced qualitative researchers using inductive and deductive techniques. A narrative, descriptive approach to the patient and clinician journey framed the study, including the development of internal journey maps, and reflexive thematic analysis was applied to the transcripts, with special attention to barriers and facilitators. Results: In total, 5 themes illustrated barriers and facilitators for participants: convenience, safety, and comfort are the benefits of telehealth for patients and clinicians; yet telehealth and in-person visits are valued differently; the convenience of telehealth may have a downside; technology acts as a double-edged sword; and managing expectations and efficiency of the visit experience was an important factor. Individual experiences varied in relation to several factors, including comfort level and access to technology, health system protocols for providing telemedicine, and level of diabetes control among patients. Conclusions: Recommendations for optimization include providing support to help guide and inform patients about what to expect and how to prepare for telehealth visits as well as allowing clinicians to schedule telehealth and in-person visits during discrete blocks of time to improve efficiency. Further research should address how hybrid models of telehealth and in-person care may differentially impact health outcomes for patients with diabetes, particularly for people with multiple chronic conditions in settings where access to technology and connectivity is not optimal.
- 1 January 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e43583
Open AccessOptimizing Telehealth for Diabetes Management in the Deep South of the United States: Qualitative Study of Barriers and Facilitators on the Patient and Clinician Journey
Background: The Deep South of the United States, and Louisiana in particular, bears a greater burden of obesity, diabetes, and heart disease compared with other regions in the United States. Throughout the COVID-19 pandemic, there has been a substantial increase in telehealth visits for diabetes management to protect the safety of patients. Although there have been significant advancements in telehealth and chronic disease management, little is known about patient and provider perspectives on the challenges and benefits of telehealth visits among people living with diabetes and providers who care for patients with diabetes in Louisiana. Objective: This study aimed to explore barriers, facilitators, challenges, and benefits to telehealth for patients with diabetes and health care providers as they transitioned from in-person to remote care during the early COVID-19 pandemic to understand potential optimization. Methods: A total of 24 semistructured qualitative interviews were conducted with 18 patients living with diabetes and 6 clinicians who served patients with diabetes to explore their experiences and perceptions of telehealth services for diabetes care. Approximately half of the participants identified as Black or African American, half as White, and 75% as female. Interviews were recorded, transcribed, and coded by experienced qualitative researchers using inductive and deductive techniques. A narrative, descriptive approach to the patient and clinician journey framed the study, including the development of internal journey maps, and reflexive thematic analysis was applied to the transcripts, with special attention to barriers and facilitators. Results: In total, 5 themes illustrated barriers and facilitators for participants: convenience, safety, and comfort are the benefits of telehealth for patients and clinicians; yet telehealth and in-person visits are valued differently; the convenience of telehealth may have a downside; technology acts as a double-edged sword; and managing expectations and efficiency of the visit experience was an important factor. Individual experiences varied in relation to several factors, including comfort level and access to technology, health system protocols for providing telemedicine, and level of diabetes control among patients. Conclusions: Recommendations for optimization include providing support to help guide and inform patients about what to expect and how to prepare for telehealth visits as well as allowing clinicians to schedule telehealth and in-person visits during discrete blocks of time to improve efficiency. Further research should address how hybrid models of telehealth and in-person care may differentially impact health outcomes for patients with diabetes, particularly for people with multiple chronic conditions in settings where access to technology and connectivity is not optimal.
- Open Access
- 9 November 2023
- Vol. 61 (12 Suppl 2) , S153-S160
Avenues for Strengthening PCORnet’s Capacity to Advance Patient-Centered Economic Outcomes in Patient-Centered Outcomes Research (PCOR)
PCORnet, the National Patient-Centered Clinical Research Network, provides the ability to conduct prospective and observational pragmatic research by leveraging standardized, curated electronic health records data together with patient and stakeholder engagement. PCORnet is funded by the Patient-Centered Outcomes Research Institute (PCORI) and is composed of 8 Clinical Research Networks that incorporate at total of 79 health system “sites.” As the network developed, linkage to commercial health plans, federal insurance claims, disease registries, and other data resources demonstrated the value in extending the networks infrastructure to provide a more complete representation of patient’s health and lived experiences. Initially, PCORnet studies avoided direct economic comparative effectiveness as a topic. However, PCORI’s authorizing law was amended in 2019 to allow studies to incorporate patient-centered economic outcomes in primary research aims. With PCORI’s expanded scope and PCORnet’s phase 3 beginning in January 2022, there are opportunities to strengthen the network’s ability to support economic patient-centered outcomes research. This commentary will discuss approaches that have been incorporated to date by the network and point to opportunities for the network to incorporate economic variables for analysis, informed by patient and stakeholder perspectives. Topics addressed include: (1) data linkage infrastructure; (2) commercial health plan partnerships; (3) Medicare and Medicaid linkage; (4) health system billing-based benchmarking; (5) area-level measures; (6) individual-level measures; (7) pharmacy benefits and retail pharmacy data; and (8) the importance of transparency and engagement while addressing the biases inherent in linking real-world data sources.
- 9 November 2023
- Vol. 61 (12 Suppl 2) , S153-S160
Open AccessAvenues for Strengthening PCORnet’s Capacity to Advance Patient-Centered Economic Outcomes in Patient-Centered Outcomes Research (PCOR)
PCORnet, the National Patient-Centered Clinical Research Network, provides the ability to conduct prospective and observational pragmatic research by leveraging standardized, curated electronic health records data together with patient and stakeholder engagement. PCORnet is funded by the Patient-Centered Outcomes Research Institute (PCORI) and is composed of 8 Clinical Research Networks that incorporate at total of 79 health system “sites.” As the network developed, linkage to commercial health plans, federal insurance claims, disease registries, and other data resources demonstrated the value in extending the networks infrastructure to provide a more complete representation of patient’s health and lived experiences. Initially, PCORnet studies avoided direct economic comparative effectiveness as a topic. However, PCORI’s authorizing law was amended in 2019 to allow studies to incorporate patient-centered economic outcomes in primary research aims. With PCORI’s expanded scope and PCORnet’s phase 3 beginning in January 2022, there are opportunities to strengthen the network’s ability to support economic patient-centered outcomes research. This commentary will discuss approaches that have been incorporated to date by the network and point to opportunities for the network to incorporate economic variables for analysis, informed by patient and stakeholder perspectives. Topics addressed include: (1) data linkage infrastructure; (2) commercial health plan partnerships; (3) Medicare and Medicaid linkage; (4) health system billing-based benchmarking; (5) area-level measures; (6) individual-level measures; (7) pharmacy benefits and retail pharmacy data; and (8) the importance of transparency and engagement while addressing the biases inherent in linking real-world data sources.
- Open Access
- 9 March 2023
- Published by Wolters Kluwer Health in Medical Care
- Vol. 61 (Suppl 1) , S77-S82
Telehealth and Medicare Type 2 Diabetes Care Outcomes
Background: At the onset of the COVID-19 pandemic, the Centers for Medicare and Medicaid Services broadened access to telehealth. This provided an opportunity to test whether diabetes, a risk factor for COVID-19 severity, can be managed with telehealth services. Objective: The objective of this study was to examine the impacts of telehealth on diabetes control. Research Design: A doubly robust estimator combined a propensity score–weighting strategy with regression controls for baseline characteristics using electronic medical records data to compare outcomes in patients with and without telehealth care. Matching on preperiod trajectories in outpatient visits and weighting by odds were used to ensure comparability between comparators. Subjects: Medicare patients with type 2 diabetes in Louisiana between March 2018 and February 2021 (9530 patients with a COVID-19 era telehealth visit and 20,666 patients without one). Measures: Primary outcomes were glycemic levels and control [ie, hemoglobin A1c (HbA1c) under 7%]. Secondary outcomes included alternative HbA1c measures, emergency department visits, and inpatient admissions. Results: Telehealth was associated with lower pandemic era mean A1c values [estimate=−0.080%, 95% confidence interval (CI): −0.111% to −0.048%], which translated to an increased likelihood of having HbA1c in control (estimate=0.013; 95% CI: 0.002–0.024; PPPP<0.001). Conclusion: Telehealth use among Medicare patients with type 2 diabetes in Louisiana stemming from the COVID-19 pandemic was associated with relatively improved glycemic control.
- 9 March 2023
- Published by Wolters Kluwer Health in Medical Care
- Vol. 61 (Suppl 1) , S77-S82
Open AccessTelehealth and Medicare Type 2 Diabetes Care Outcomes
Background: At the onset of the COVID-19 pandemic, the Centers for Medicare and Medicaid Services broadened access to telehealth. This provided an opportunity to test whether diabetes, a risk factor for COVID-19 severity, can be managed with telehealth services. Objective: The objective of this study was to examine the impacts of telehealth on diabetes control. Research Design: A doubly robust estimator combined a propensity score–weighting strategy with regression controls for baseline characteristics using electronic medical records data to compare outcomes in patients with and without telehealth care. Matching on preperiod trajectories in outpatient visits and weighting by odds were used to ensure comparability between comparators. Subjects: Medicare patients with type 2 diabetes in Louisiana between March 2018 and February 2021 (9530 patients with a COVID-19 era telehealth visit and 20,666 patients without one). Measures: Primary outcomes were glycemic levels and control [ie, hemoglobin A1c (HbA1c) under 7%]. Secondary outcomes included alternative HbA1c measures, emergency department visits, and inpatient admissions. Results: Telehealth was associated with lower pandemic era mean A1c values [estimate=−0.080%, 95% confidence interval (CI): −0.111% to −0.048%], which translated to an increased likelihood of having HbA1c in control (estimate=0.013; 95% CI: 0.002–0.024; PPPP<0.001). Conclusion: Telehealth use among Medicare patients with type 2 diabetes in Louisiana stemming from the COVID-19 pandemic was associated with relatively improved glycemic control.
- Open Access
- 24 October 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Optimizing Telehealth for Diabetes Management in the Deep South of the United States: Qualitative Study of Barriers and Facilitators on the Patient and Clinician Journey (Preprint)
BACKGROUND The Deep South of the United States, and Louisiana in particular, bears a greater burden of obesity, diabetes, and heart disease compared with other regions in the United States. Throughout the COVID-19 pandemic, there has been a substantial increase in telehealth visits for diabetes management to protect the safety of patients. Although there have been significant advancements in telehealth and chronic disease management, little is known about patient and provider perspectives on the challenges and benefits of telehealth visits among people living with diabetes and providers who care for patients with diabetes in Louisiana. OBJECTIVE This study aimed to explore barriers, facilitators, challenges, and benefits to telehealth for patients with diabetes and health care providers as they transitioned from in-person to remote care during the early COVID-19 pandemic to understand potential optimization. METHODS A total of 24 semistructured qualitative interviews were conducted with 18 patients living with diabetes and 6 clinicians who served patients with diabetes to explore their experiences and perceptions of telehealth services for diabetes care. Approximately half of the participants identified as Black or African American, half as White, and 75% as female. Interviews were recorded, transcribed, and coded by experienced qualitative researchers using inductive and deductive techniques. A narrative, descriptive approach to the patient and clinician journey framed the study, including the development of internal journey maps, and reflexive thematic analysis was applied to the transcripts, with special attention to barriers and facilitators. RESULTS In total, 5 themes illustrated barriers and facilitators for participants: convenience, safety, and comfort are the benefits of telehealth for patients and clinicians; yet telehealth and in-person visits are valued differently; the convenience of telehealth may have a downside; technology acts as a double-edged sword; and managing expectations and efficiency of the visit experience was an important factor. Individual experiences varied in relation to several factors, including comfort level and access to technology, health system protocols for providing telemedicine, and level of diabetes control among patients. CONCLUSIONS Recommendations for optimization include providing support to help guide and inform patients about what to expect and how to prepare for telehealth visits as well as allowing clinicians to schedule telehealth and in-person visits during discrete blocks of time to improve efficiency. Further research should address how hybrid models of telehealth and in-person care may differentially impact health outcomes for patients with diabetes, particularly for people with multiple chronic conditions in settings where access to technology and connectivity is not optimal.
- 24 October 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessOptimizing Telehealth for Diabetes Management in the Deep South of the United States: Qualitative Study of Barriers and Facilitators on the Patient and Clinician Journey (Preprint)
BACKGROUND The Deep South of the United States, and Louisiana in particular, bears a greater burden of obesity, diabetes, and heart disease compared with other regions in the United States. Throughout the COVID-19 pandemic, there has been a substantial increase in telehealth visits for diabetes management to protect the safety of patients. Although there have been significant advancements in telehealth and chronic disease management, little is known about patient and provider perspectives on the challenges and benefits of telehealth visits among people living with diabetes and providers who care for patients with diabetes in Louisiana. OBJECTIVE This study aimed to explore barriers, facilitators, challenges, and benefits to telehealth for patients with diabetes and health care providers as they transitioned from in-person to remote care during the early COVID-19 pandemic to understand potential optimization. METHODS A total of 24 semistructured qualitative interviews were conducted with 18 patients living with diabetes and 6 clinicians who served patients with diabetes to explore their experiences and perceptions of telehealth services for diabetes care. Approximately half of the participants identified as Black or African American, half as White, and 75% as female. Interviews were recorded, transcribed, and coded by experienced qualitative researchers using inductive and deductive techniques. A narrative, descriptive approach to the patient and clinician journey framed the study, including the development of internal journey maps, and reflexive thematic analysis was applied to the transcripts, with special attention to barriers and facilitators. RESULTS In total, 5 themes illustrated barriers and facilitators for participants: convenience, safety, and comfort are the benefits of telehealth for patients and clinicians; yet telehealth and in-person visits are valued differently; the convenience of telehealth may have a downside; technology acts as a double-edged sword; and managing expectations and efficiency of the visit experience was an important factor. Individual experiences varied in relation to several factors, including comfort level and access to technology, health system protocols for providing telemedicine, and level of diabetes control among patients. CONCLUSIONS Recommendations for optimization include providing support to help guide and inform patients about what to expect and how to prepare for telehealth visits as well as allowing clinicians to schedule telehealth and in-person visits during discrete blocks of time to improve efficiency. Further research should address how hybrid models of telehealth and in-person care may differentially impact health outcomes for patients with diabetes, particularly for people with multiple chronic conditions in settings where access to technology and connectivity is not optimal.
- 1 October 2020
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 34 (10) , 107663
The impact of Medicaid expansion on access to care and preventive care for adults with diabetes and depression
- 1 October 2020
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 34 (10) , 107663
The impact of Medicaid expansion on access to care and preventive care for adults with diabetes and depression
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
42-LB: Factors Associated with Use of Diabetes Self-Management Education and Support Programs in Newly Diagnosed Type 2 Diabetes Patients in Louisiana
Background: Prevalence of and factors associated with use of diabetes self-management education and support (DSME/S) programs in newly diagnosed type 2 diabetes (T2D) patients in Louisiana (LA) have not been fully evaluated. Methods: We used EHRs from 3 hospital systems in LA (01/01/2013 to 10/31/2019). Eligible patients were 35-94 y-old with T2D based on ICD-codes, an antidiabetic drug prescription, an HbA1c ≥6.5%, an FPG ≥126, a 2-hr OGT ≥200, or random plasma glucose ≥200 mg/dL. New T2D was defined as entry of T2D diagnosis in the condition list occurring ≥1 y after first recorded office visit. DSME/S were searched by HCPCS codes G0108 and G0109. Logistic regressions compared differences between DSME/S vs. non-DSME/S group ≥180 days before the first recorded DSME/S. Results: The prevalence of DSME/S use in T2D patients was 5.6% (18,139/313,242). In newly diagnosed T2D patients, the prevalence was 6.2% (8,918/137,629). Comparing to gender-, age- and race-matched non-DSME/S group, DSME/S group had worse clinical profiles, e.g., higher mean A1c and triglycerides, lower mean HDL, and higher obesity rate. Adjusted models showed self-pay patients were 70% less likely (OR 0.3, 95% CI 0.2-0.6) to use DMSE/S than Medicare beneficiaries. Current smokers were 2.6 times more likely (2.6, 1.8-3.7), but former smokers were 40% less likely (0.6, 0.5-0.7) to use DMSE/S than never smokers. Patients with hypolipidemic or antihypertensive drugs were 50% (1.5, 1.4-1.8) or 60% (1.6, 1.4-1.8) more likely to use DSME/S than those without the medications. Patients with A1c >6.5% were 3.9 times more likely (3.9, 3.4-4.6) to use DSMES/S than those with normal A1c. Obese patients were 60% more likely (1.6, 1.4-1.9), but hypertensive patients (SBP>130/DBP>80 mmHg) were 60% less likely to use DSME/S (0.4, 0.3-0.5). Conclusion: Use of DSME/S is low in LA, and there are marked differences in using the service by insurance type, smoking status and diabetes risk control. Disclosure: Y. Yoshida: None. L. Shi: None. D. Hong: None. E. Nauman: None. G. Hu: None. P.T. Katzmarzyk: None. E.G. Price-Haywood: None. A.N. Bazzano: None. Y. Shen: None. V. Fonseca: Consultant; Self; Abbott, Asahi Kasei Corporation, AstraZeneca, Bayer Inc., Novo Nordisk Inc., Sanofi. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc. Stock/Shareholder; Self; Amgen, Bravo4health.
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
42-LB: Factors Associated with Use of Diabetes Self-Management Education and Support Programs in Newly Diagnosed Type 2 Diabetes Patients in Louisiana
Background: Prevalence of and factors associated with use of diabetes self-management education and support (DSME/S) programs in newly diagnosed type 2 diabetes (T2D) patients in Louisiana (LA) have not been fully evaluated. Methods: We used EHRs from 3 hospital systems in LA (01/01/2013 to 10/31/2019). Eligible patients were 35-94 y-old with T2D based on ICD-codes, an antidiabetic drug prescription, an HbA1c ≥6.5%, an FPG ≥126, a 2-hr OGT ≥200, or random plasma glucose ≥200 mg/dL. New T2D was defined as entry of T2D diagnosis in the condition list occurring ≥1 y after first recorded office visit. DSME/S were searched by HCPCS codes G0108 and G0109. Logistic regressions compared differences between DSME/S vs. non-DSME/S group ≥180 days before the first recorded DSME/S. Results: The prevalence of DSME/S use in T2D patients was 5.6% (18,139/313,242). In newly diagnosed T2D patients, the prevalence was 6.2% (8,918/137,629). Comparing to gender-, age- and race-matched non-DSME/S group, DSME/S group had worse clinical profiles, e.g., higher mean A1c and triglycerides, lower mean HDL, and higher obesity rate. Adjusted models showed self-pay patients were 70% less likely (OR 0.3, 95% CI 0.2-0.6) to use DMSE/S than Medicare beneficiaries. Current smokers were 2.6 times more likely (2.6, 1.8-3.7), but former smokers were 40% less likely (0.6, 0.5-0.7) to use DMSE/S than never smokers. Patients with hypolipidemic or antihypertensive drugs were 50% (1.5, 1.4-1.8) or 60% (1.6, 1.4-1.8) more likely to use DSME/S than those without the medications. Patients with A1c >6.5% were 3.9 times more likely (3.9, 3.4-4.6) to use DSMES/S than those with normal A1c. Obese patients were 60% more likely (1.6, 1.4-1.9), but hypertensive patients (SBP>130/DBP>80 mmHg) were 60% less likely to use DSME/S (0.4, 0.3-0.5). Conclusion: Use of DSME/S is low in LA, and there are marked differences in using the service by insurance type, smoking status and diabetes risk control. Disclosure: Y. Yoshida: None. L. Shi: None. D. Hong: None. E. Nauman: None. G. Hu: None. P.T. Katzmarzyk: None. E.G. Price-Haywood: None. A.N. Bazzano: None. Y. Shen: None. V. Fonseca: Consultant; Self; Abbott, Asahi Kasei Corporation, AstraZeneca, Bayer Inc., Novo Nordisk Inc., Sanofi. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc. Stock/Shareholder; Self; Amgen, Bravo4health.
- Open Access
- 31 January 2020
- Published by Korean Stroke Society in Journal of Stroke
- Vol. 22 (1) , 87-98
Association between Hemoglobin A1c and Stroke Risk in Patients with Type 2 Diabetes
Background and Purpose The association between hemoglobin A1c (HbA1c) and stroke risk along with its subtypes is rarely reported. We aimed to investigate the association between HbA1c and the risk of incident stroke in patients with type 2 diabetes based on real world data from three healthcare systems.Methods We performed a retrospective cohort study of 27,113 African Americans and 40,431 whites with type 2 diabetes. Demographic, anthropometric, laboratory, and medication information were abstracted from the National Patient-Centered Clinical Research Network common data model. Incident stroke events including both ischemic and hemorrhagic stroke were defined.Results During a mean follow-up period of 3.79±1.68 years, 7,735 patients developed stroke (6,862 ischemic and 873 hemorrhagic). Multivariable-adjusted hazard ratios across levels of HbA1c at baseline (<6.0%, 6.0% to 6.9% [reference group], 7.0% to 7.9%, 8.0% to 8.9%, 9.0% to 9.9%, and ≥10%) were 1.07, 1.00, 1.13, 1.23, 1.27, and 1.37 (Ptrend <0.001) for total stroke, 1.02, 1.00, 1.13, 1.20, 1.24, and 1.35 (Ptrend <0.001) for ischemic stroke, and 1.40, 1.00, 1.14, 1.47, 1.47, and 1.51 (Ptrend=0.002) for hemorrhagic stroke. When we used an updated mean value of HbA1c, the U-shaped association of HbA1c with stroke risk did not change. This U-shaped association was consistent among patients of different subgroups. The U-shaped association was more pronounced among patients taking antidiabetic, lipid-lowering, and antihypertensive medications compared with those without these medications.Conclusions These data suggest that diabetes management may have to be individualized according to the guideline recommendations rather than intensively attempting to lower HbA1c.
- 31 January 2020
- Published by Korean Stroke Society in Journal of Stroke
- Vol. 22 (1) , 87-98
Open AccessAssociation between Hemoglobin A1c and Stroke Risk in Patients with Type 2 Diabetes
Background and Purpose The association between hemoglobin A1c (HbA1c) and stroke risk along with its subtypes is rarely reported. We aimed to investigate the association between HbA1c and the risk of incident stroke in patients with type 2 diabetes based on real world data from three healthcare systems.Methods We performed a retrospective cohort study of 27,113 African Americans and 40,431 whites with type 2 diabetes. Demographic, anthropometric, laboratory, and medication information were abstracted from the National Patient-Centered Clinical Research Network common data model. Incident stroke events including both ischemic and hemorrhagic stroke were defined.Results During a mean follow-up period of 3.79±1.68 years, 7,735 patients developed stroke (6,862 ischemic and 873 hemorrhagic). Multivariable-adjusted hazard ratios across levels of HbA1c at baseline (<6.0%, 6.0% to 6.9% [reference group], 7.0% to 7.9%, 8.0% to 8.9%, 9.0% to 9.9%, and ≥10%) were 1.07, 1.00, 1.13, 1.23, 1.27, and 1.37 (Ptrend <0.001) for total stroke, 1.02, 1.00, 1.13, 1.20, 1.24, and 1.35 (Ptrend <0.001) for ischemic stroke, and 1.40, 1.00, 1.14, 1.47, 1.47, and 1.51 (Ptrend=0.002) for hemorrhagic stroke. When we used an updated mean value of HbA1c, the U-shaped association of HbA1c with stroke risk did not change. This U-shaped association was consistent among patients of different subgroups. The U-shaped association was more pronounced among patients taking antidiabetic, lipid-lowering, and antihypertensive medications compared with those without these medications.Conclusions These data suggest that diabetes management may have to be individualized according to the guideline recommendations rather than intensively attempting to lower HbA1c.
- Open Access
- 20 November 2018
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 7 (11) , 451
Barriers and Facilitators in Implementing Non-Face-to-Face Chronic Care Management in an Elderly Population with Diabetes: A Qualitative Study of Physician and Health System Perspectives
The burden of illness related to diabetes and its complications is exceedingly high and growing globally. Systematic approaches to managing chronic care are needed to address the complex nature of the disease, taking into account health system structures. This study presents data collected from interviews with physicians, health system administrators, and other healthcare staff about chronic care management for elderly people with diabetes co-morbid with other chronic conditions in light of new programs intended to reduce barriers by incentivizing care encounters that take place through telephone and electronic communications (non-face-to-face care). Results indicate that health system personnel view non-face-to-face care as potentially providing value for patients and addressing systemic needs, yet challenging to implement in practice. Barriers and facilitators to this approach for managing diabetes and chronic care management for its complications are presented, with consideration to different types of health systems, and recommendations are provided for implementation.
- 20 November 2018
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 7 (11) , 451
Open AccessBarriers and Facilitators in Implementing Non-Face-to-Face Chronic Care Management in an Elderly Population with Diabetes: A Qualitative Study of Physician and Health System Perspectives
The burden of illness related to diabetes and its complications is exceedingly high and growing globally. Systematic approaches to managing chronic care are needed to address the complex nature of the disease, taking into account health system structures. This study presents data collected from interviews with physicians, health system administrators, and other healthcare staff about chronic care management for elderly people with diabetes co-morbid with other chronic conditions in light of new programs intended to reduce barriers by incentivizing care encounters that take place through telephone and electronic communications (non-face-to-face care). Results indicate that health system personnel view non-face-to-face care as potentially providing value for patients and addressing systemic needs, yet challenging to implement in practice. Barriers and facilitators to this approach for managing diabetes and chronic care management for its complications are presented, with consideration to different types of health systems, and recommendations are provided for implementation.